Laser Away Pesky Skin Growths: Could Nd-YAG Be Your Answer?
"Discover how Nd-YAG laser treatment offers a safe and effective alternative for removing pyogenic granulomas on fingers and toes, especially when surgery isn't ideal."
Pyogenic granulomas (PGs) are common, non-cancerous skin growths that appear as small, raised bumps, often red or dark in color. While they can occur anywhere on the body, they're frequently found on the head, neck, hands, and feet. These lesions are typically characterized by rapid growth and a tendency to bleed easily, even with minor trauma.
When it comes to treating PGs, several options exist, ranging from surgical excision to cryotherapy and topical medications. Surgical removal is often considered the most effective, offering the lowest recurrence rates and allowing for a definitive diagnosis through biopsy. However, surgery can be challenging when lesions are located on the fingers and toes, particularly if they're close to the nails.
That's where laser treatment comes in. This article explores the use of the neodymium-yttrium aluminum garnet (Nd-YAG) laser as a safe and effective alternative for treating PGs on the fingers and toes. We'll delve into a recent study that investigated the clinical efficacy and safety of this approach, offering insights into how it works and what results you can expect.
A Common, Recurring Skin Complaint
Pyogenic granuloma is a benign vascular tumor that can develop on the skin and occasionally the oral cavity, and it is among the more common skin growths people seek treatment for. Because it grows rapidly and tends to bleed easily, many patients want it removed despite its non-cancerous nature. Available data on exactly how common it is remain limited, and figures differ depending on the population studied and the site of the lesions. The frequent recurrence after some treatments is what drives much of the ongoing clinical interest in laser-based approaches.
From Surgery to Combined Laser Therapy
Conventional management of pyogenic granuloma historically centers on surgical removal, yet surgery carries well-documented complications: a PubMed/Medline search combining "pyogenic granuloma" and "surgery" returned 1171 studies, of which those passing inclusion criteria specifically flagged intervention-associated complications occurring at rates over 5 percent. Because of these limitations, clinicians have increasingly turned to lasers. In one series, 20 patients were treated with a combination of long-pulse 1064nm Nd:YAG laser and pulsed CO2 laser plus photodynamic therapy using aminolevulinic acid hydrochloride, with efficacy, recurrence, and safety checked at 1 and 2 months post-treatment. The investigators reported the combined therapy as highly effective, with no recurrences and minimal adverse reactions, and observed significantly improved patient satisfaction. A separate retrospective study directly compared long-pulsed 1064 nm Nd:YAG laser against sclerotherapy for pyogenic granuloma in children, reflecting a broader push to find effective, low-trauma alternatives to conventional surgery.
From Sclerotherapy to the Nd:YAG Era
Treatment of pyogenic granuloma has evolved over decades, and its history is not marked by a single breakthrough so much as a steady expansion of available tools. Early mainstream options relied on surgical excision and destructive methods, which worked but left patients with the risk of bleeding and recurrence. The introduction of vascular lasers introduced a less invasive alternative, and this was gradually refined with longer pulse durations engineered to close vessels while sparing surrounding skin. Sclerotherapy also emerged as an established option in many practices. The field's trajectory reflects a gradual shift toward modalities that aim to match old cure rates with better cosmetic and recovery outcomes.
Nd-YAG Laser: A Gentle but Effective Solution for PGs?
The study evaluated twenty-one patients with PGs located on their fingers and toes. Each patient received multispot Nd-YAG laser treatments, with the laser targeting the lesions using a monopulse setting (pulse width 10.5–13.5 ms; energy 100–125 J/cm²). Treatments were spaced 3–4 weeks apart, allowing the skin to heal between sessions.
- High Success Rate: All lesions disappeared after just one or two laser treatments.
- Minimal Scarring: There was no noticeable scar formation in any of the patients.
- No Functional Impact: The treatment didn't affect the function of the fingers and toes.
- No Nail Damage: There was no damage to nail growth.
- Low Recurrence: No PGs returned during the 12-month follow-up period.
Recent Clinical Evidence for Nd:YAG
Recent work has focused on both Nd:YAG laser alone and Nd:YAG combined with other modalities for pyogenic granuloma. A case report by Kocaman et al. described the use of Nd:YAG laser in treating pyogenic granuloma, noting a shortened operative time, rapid postoperative hemostasis, and no scarring. In a January 2025 article published in Scientific Reports, Cheng and colleagues retrospectively compared long-pulsed 1064 nm Nd:YAG laser with sclerotherapy for pyogenic granuloma in children, adding pediatric data to a literature that has largely involved adults. Alongside these, a 2025 clinical observation study reported that combined long-pulse 1064nm Nd:YAG laser, pulsed CO2 laser, and photodynamic therapy was highly effective in treating pyogenic granuloma, with no recurrences, minimal adverse reactions, and significantly improved patient satisfaction. Together these studies illustrate growing confidence in Nd:YAG-based treatment as recurrence and adverse-event rates continue to be reported and compared.
Not All Laser Outcomes Are Equal
Closer scrutiny shows that Nd:YAG laser outcomes are not uniformly perfect, and much of the uncertainty centers on children, where use of the 1064 nm long-pulsed Nd:YAG laser for pyogenic granuloma has rarely been reported. Cheng and colleagues' retrospective study was designed precisely to analyze the effectiveness and safety of this laser among pediatric patients attending a Dermatology Laser Clinic for laser therapy. Their data showed that after two treatments the cure rate was 78.0 percent in the Gentle Nd:YAG laser group versus 83.9 percent in the sclerotherapy group, even though the total effective rate reached 100 percent in both groups. The same report documented a facial pyogenic granuloma that disappeared completely two months after sclerotherapy without scarring or pigmentation. These numbers are a reminder that laser cure rates can trail those of alternative treatments, and that efficacy claims should be weighed against comparative data rather than taken at face value.
Combined Laser Therapy vs. Sclerotherapy
The comparative picture for pyogenic granuloma treatment comes largely from Cheng and colleagues' retrospective study in Scientific Reports, which contrasted long-pulsed 1064 nm Nd:YAG laser with sclerotherapy in children. In that analysis, the Gentle Nd:YAG laser group achieved a cure rate of 78.0 percent after two treatments, while the sclerotherapy group reached 83.9 percent, with both groups posting a 100 percent total effective rate. On the other side of the ledger, a separate clinical observation of combined long-pulse 1064nm Nd:YAG laser, pulsed CO2 laser, and photodynamic therapy reported the approach as highly effective, with no recurrences, minimal adverse reactions, and significantly improved patient satisfaction. Read together, the two bodies of evidence suggest that single-modality Nd:YAG laser may need to compete hard against sclerotherapy's cure rates, while the combined laser-plus-photodynamic therapy regimen appears to offer a stronger standalone result. The differing outcomes highlight how the specific laser parameters and additional modalities matter when choosing among options.
The Future of PG Treatment: Is Laser Therapy Right for You?
The study's findings support the use of Nd-YAG laser as a promising treatment option for pyogenic granulomas, particularly in sensitive areas like the fingers and toes. Its non-invasive nature, minimal scarring, and low recurrence rates make it an attractive alternative to surgical excision.
The State of the Evidence
Taken as a whole, the emerging literature paints a cautiously optimistic picture for Nd:YAG laser therapy of pyogenic granuloma, while also making clear that the evidence base is still building. The most positive results come from studies that pair Nd:YAG with other modalities, such as pulsed CO2 laser and photodynamic therapy, where authors report no recurrences and high satisfaction. Comparative data in children, however, suggest that Nd:YAG laser alone may not always outperform well-established alternatives like sclerotherapy. Experts would likely emphasize that treatment choice still depends on lesion size, location, patient age, and clinician experience.
Where the Field Is Heading
The next generation of pyogenic granuloma treatment will likely be shaped by larger, prospective studies that confirm what current retrospective series have suggested. Refining laser parameters and combination protocols, especially for pediatric patients, appears to be a promising direction. Comparisons that track long-term recurrence, scarring, and patient satisfaction across age groups will help clarify when Nd:YAG is the right first-line choice. If these studies confirm current signals, laser-based care may increasingly replace more invasive options for this common benign growth.
Study Size, Follow-Up, and Reproducibility
A key systemic challenge in this area is the modest size of the underlying studies. In one clinical observation, only 20 patients with pyogenic granuloma were treated with a combination of long-pulse 1064nm Nd:YAG laser, pulsed CO2 laser, and topical aminolevulinic acid hydrochloride for photodynamic therapy, with efficacy, recurrence, and safety monitored at just 1 and 2 months post-treatment. Such small cohorts and short follow-up windows make it difficult to generalize the reported outcomes or to understand longer-term recurrence behavior. Replicating these results across different clinics and larger pediatric and adult populations will be essential before combined Nd:YAG protocols can be considered a definitive standard of care rather than a promising early finding.
What It Means for Patients
For patients, the practical stakes of these findings are lower risk of recurrence, quicker recovery, and less scarring after removal of a benign but bothersome growth. A lesion that bleeds easily can be distressing in daily life, and anxiety about appearance or cancer often prompts the visit even when the growth is harmless. Knowing that treatments exist with reported minimal adverse reactions and no recurrences may ease that anxiety, though patients should understand that individual results vary. Ultimately the choice between laser, combined therapy, and sclerotherapy should be made with a clinician who can weigh the specific characteristics of the lesion.
Of course, it's essential to consult with a qualified dermatologist or medical professional to determine the best course of treatment for your specific situation. They can assess your lesion, discuss the potential benefits and risks of each option, and help you make an informed decision.
With ongoing advancements in laser technology, non-surgical treatments for skin conditions like pyogenic granulomas are becoming increasingly effective and accessible. The Nd-YAG laser represents a significant step forward, offering a gentle yet powerful solution for removing these pesky skin growths and restoring your skin's health and appearance.